FDA Approves New Targeted Therapy Doubling Survival in Metastatic Pancreatic Cancer
Translated & summarized from Now 14 by baba
The FDA approved daraxonrasib, a targeted drug for metastatic pancreatic cancer with RAS mutations, after a trial showed it nearly doubled median survival compared to chemotherapy. The oral treatment marks a significant advance for this hard-to-treat cancer, though availability in Israel requires further regulatory steps.
The story in 6 lines · by baba
- FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma with RAS mutations.
- Clinical trial with 500 patients showed median survival of 13.2 vs. 6.7 months over chemotherapy.
- Daraxonrasib is the first RAS inhibitor approved for pancreatic cancer treatment.
- Common side effects include rash, diarrhea, nausea, and fatigue, with serious risks requiring monitoring.
- FDA granted accelerated development designations before final approval.
- Israeli availability depends on local registration and funding decisions.
The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a new targeted treatment for adults with metastatic pancreatic adenocarcinoma harboring RAS mutations. This approval follows a large randomized clinical trial involving 500 patients, which demonstrated a median overall survival of 13.2 months for those treated with daraxonrasib, compared to 6.7 months for patients receiving standard chemotherapy. The drug, administered orally once daily, inhibits multiple active forms of RAS proteins, which play a key role in cell growth and division and are commonly mutated in pancreatic cancer.
Pancreatic cancer is notoriously difficult to treat and often diagnosed late due to a lack of specific symptoms. Approximately 90-95% of pancreatic cancer cases in the U.S. are adenocarcinomas, the subtype targeted by this new therapy. Common side effects reported include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, and appetite loss, with warnings for serious adverse effects requiring medical monitoring.
The FDA granted daraxonrasib accelerated development designations such as Breakthrough Therapy and Priority Review prior to approval. However, this FDA approval does not automatically authorize the drug's availability in Israel, where local registration and funding decisions will determine its accessibility. This advancement also highlights a broader shift in oncology towards treatments tailored to the molecular characteristics of tumors rather than solely their anatomical location, suggesting genomic testing may become increasingly important for pancreatic cancer treatment selection.
Mentioned
